Investor Presentaiton

Advancing and augmenting our operational excellence ■ - ■ 1 Operational excellence 2 Value enhancing BD Expanded application of new edge technology into small molecules like; Flow Chemistry, Bio catalysis, Precision fermentation Λ Stabilization of ARV business and achieved over 50% of targeted cost improvement initiatives Grown Scientific and Commercial advantage to onboard new clients Fully automated manufacturing line implemented DP including ODFS 51 quality audits completed Implemented SANKALP (in alliance with DSS+) to enhance Organizational Safety excellence ^ Process, Procurements and Integration, 1 R/R=relapsed refractory 6 3 Transformative technology ☐ ☐ Multi-Year Commercial Contract with leading Global Crop Science company signed and further deepening engagement; potentially diversifies CDMO portfolio Commercial activity initiated from Animal health site LSPL-U2 from Oct'23 Global supply chain migration leading to new CMO opportunities India's first CAR-T cell therapy, NexCAR19 approved from CDSCO on 12-Oct/23 to treat r/r Lymphoma/Leukemia indication Increased stake in Cell therapy company ImmunoACT to ~34% CAR-T treatment capacity expansion to service more patients Collaboration with IIT Kanpur to in- license and fund development of Gene therapy assets. GLP lab construction work initiated for AAV Vectors and Gene Therapy Products Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation